Lakewood‑Amedex reports strong preclinical results for Bisphosphocin compounds in urinary and lung infection models
Lakewood‑Amedex Biotherapeutics announced that its Bisphosphocin compound Nu‑8 inhibited up to 97% of E. coli growth in a rodent urinary‑tract infection study using a 10% solution. The same class showed activity in animal studies of pulmonary infections when delivered as an aerosol, targeting Acinetobacter species, Pseudomonas aeruginosa and Aspergillus fumigatus. The company’s lead candidate, Nu‑3, a topical gel for diabetic foot ulcers, remains in a Phase 2a trial with topline data expected in the first quarter of 2027.
Why it matters
The positive preclinical data may improve investor confidence in the Bisphosphocin platform and support future financing or partnership opportunities, as the company advances candidates toward early clinical development.
Key facts
- 1Nu‑8 achieved up to 97% inhibition of E. coli growth in a rodent urinary‑tract infection model using a 10% solution. prnewswire.com
- 2Bisphosphocin compounds demonstrated activity in animal studies of lung infections when administered as an aerosol, affecting Acinetobacter species, Pseudomonas aeruginosa and Aspergillus fumigatus. prnewswire.com
- 3The Bisphosphocin class showed in‑vitro activity against resistant bacteria such as E. coli, K. pneumoniae and P. aeruginosa. prnewswire.com
- 4Lead candidate Nu‑3 is being tested in an ongoing Phase 2a trial for mildly infected diabetic foot ulcers. prnewswire.com
- 5Topline results from the Phase 2a trial are expected in the first quarter of 2027. prnewswire.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.